Accredited Investors Employee Shareholders Institutions Private Companies Who We Serve Trading and InvestingData SolutionsPrivate Asset Custody Institutional TradingForge ProTrade private companies with Forge’s institutional brokerage toolBrowse CompaniesIndividual InvestingForge MarketsFind new private company investment opportunitiesForge DataAnalyze private markets via Forge’s intuitive web applicationForge Private Market IndexMonitor a benchmark for actively traded private companies Forge Accuidity Private Market IndexInvest in an institutionally-managed diversified basket of private companies (QPs only)Self-Directed IRAForge TrustInvest in private companies and other alternative assets through a tax-advantaged Self-Directed IRASolutions All InsightsPrivate Market ReportsMarket InsightsBuying and Selling Pre-IPO All ReportsPrivate Market Updates Forge Investment OutlookStartup News and TrendsPrivate Market Data and AnalyticsTech IPO Calendar for 2024Private Market ExplainedBuying Pre-IPO SharesSelling Pre-IPO Shares Glossary Videos FAQsInsights About Us Leadership Investor Relations People & Culture Careers About

Cour Pharmaceuticals Development Stock

Q: How to sell Cour Pharmaceuticals Development stock?

If you hold private company shares of Cour Pharmaceuticals Development - whether as an employee or an early investor - Forge can help you sell them. 1. Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have. 2. Indicate your interest to sell your Cour Pharmaceuticals Development stock on our platform. 3. Work with your dedicated Private Market Specialist who’ll help guide you through every step of the transaction.

www.courpharma.comHealthcare / BioTech & PharmaFounded: 2012

COUR Pharmaceuticals aims to advance novel therapies that reprogram the immune system for antigen-specific tolerance, focusing on the root of immune-mediated diseases. Their cutting-edge nanoparticle platform diverges from traditional symptom-suppressing treatments, offering a more targeted approach. Collaborating with Takeda on a leading celiac disease therapy, COUR has achieved the first instance of antigen-specific immune tolerance in autoimmune diseases. This breakthrough underscores the potential of their platform to address a wide array of immune and inflammatory conditions.

Buy or sell Cour Pharmaceuticals Development stockLearn more about Cour Pharmaceuticals Development IPO

OverviewFinancingsValuation

Enterprise Value

Access Cour Pharmaceuticals Development’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Cour Pharmaceuticals Development.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Access Stock Price

Animation displayed is not current and securities are shown for illustrative purposes only.

Cour Pharmaceuticals Development investors also invested in these private companies

Bristol Myers Squibb

Attralus, Capstan Therapeutics, Zenas BioPharma, BigHat Biosciences, Vedanta Biosciences, Cour Pharmaceuticals Development, Aktis Oncology, Accent Therapeutics, Cellares, Obsidian Therapeutics

T1D Fund

Cour Pharmaceuticals Development, Bigfoot Biomedical

Chimera Capital

CMR Surgical, Mindtickle, Forward, Synthego, Cour Pharmaceuticals Development, Lenskart, Agile Robots

Lumira Ventures

HistoSonics, Antiva Biosciences, Cour Pharmaceuticals Development, Cardiac Dimensions

Alpha Wave Global

Feastables, Apnimed, Athletic Greens, Attralus, Moonwalk Biosciences, Lenskart, Human Immunology Biosciences, Cour Pharmaceuticals Development, Gamma, Alto Neuroscience

Pfizer Ventures

Resilience, Capstan Therapeutics, Cour Pharmaceuticals Development, RefleXion Medical, Flare Therapeutics

Angelini Ventures

Cour Pharmaceuticals Development, Noctrix Health

Roche Venture Fund

Freenome, Cour Pharmaceuticals Development

Team

Management Team

John Puisis

Co-Founder, President & Chief Executive Officer

Stephen Miller Ph.D

Co-Founder

Roy First MD

Chief Medical Officer

Brian Bock

Chief Financial Officer

Dannielle Appelhans

Chief Operating Officer

Sarah Longoria

Chief People Officer

Board Members

Chris Dimitropoulos

Alpha Wave Global

Cour Pharmaceuticals Development stock FAQs

Can you buy Cour Pharmaceuticals Development stock?

As Cour Pharmaceuticals Development is not publicly traded, purchasing its stock is not available to everyone. To buy the stock of a private company like Cour Pharmaceuticals Development, you must be an accredited investor. If you meet the accreditation criteria, you can register for Forge’s Secondary Marketplace to buy private market stock. If you are not an accredited investor, discover how to begin the process to potentially qualify for new investment opportunities.

How to buy Cour Pharmaceuticals Development stock?

To invest in a private company like Cour Pharmaceuticals Development through Forge, you must first qualify as an accredited investor. (Learn more about the accreditation process.)

Create a free account to access Forge’s marketplace.
Express your interest in specific investments. Within Forge Markets, you will find detailed pricing and financing information for thousands of private companies.
Throughout this process, a dedicated Forge Private Market Specialist will be available to address any questions you may have and to guide you seamlessly through each step of the transaction.

Can you sell Cour Pharmaceuticals Development stock?

Yes, you may be able to sell your Cour Pharmaceuticals Development stock, subject to certain conditions. Forge can help you facilitate the sale of your stock in a manner that aligns with your needs and the company's interests. If you are looking for liquidity, register with us today to begin the process. A dedicated Forge Private Market Specialist will be available to address any questions you may have along the way.

How to sell Cour Pharmaceuticals Development stock?

If you hold private company shares of - whether as an employee or an early investor - Forge can help you sell them.

Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have.
Indicate your interest to sell your Cour Pharmaceuticals Development stock on our platform.
Work with your dedicated Private Market Specialist who'll help guide you through every step of the transaction.

Is Cour Pharmaceuticals Development a public company?

No, Cour Pharmaceuticals Development is a privately held company and is currently not publicly traded on any stock markets including NYSE or NASDAQ.

What is Cour Pharmaceuticals Development’s stock price?

Cour Pharmaceuticals Development is a privately held company and therefore does not have a public stock price. However, you may access Cour Pharmaceuticals Development’s private market stock price with Forge Data.

What is Cour Pharmaceuticals Development’s stock ticker symbol?

Cour Pharmaceuticals Development does not have an official ticker symbol because this company is not currently publicly traded.

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

BioSpace 01/31/2024

Cour Raises $105M in Series A Round with Backing From Big Pharma

Illinois-based Cour Pharmaceuticals on Tuesday announced that it raised $105 million in Series A funding to help the company advance multiple, wholly-owned candidates. The investment was led by Lumira Ventures and Alpha Wave Ventures and had participation from Bristol Myers Squibb, Pfizer Breakthrough Growth Initiatives and Roche Ventures. Angelini Ventures and the DJRF T1D Fund also participated.

STAT+ 01/30/2024

Cour Pharmaceuticals, a biotech taking aim at autoimmune diseases, raises $105 million

The group was developing a sort of Trojan horse that it hoped could be used to treat autoimmune diseases. They had developed polymer nanoparticles that could mimic dying cells, which the immune system won’t attack, but will naturally pull from the bloodstream and throw into the body’s waste collection and recycling systems — the spleen and liver — for disposal. Inside of the polymer nanoparticles, they could hide disease-specific antigen that could begin correcting the immune system’s overreaction to certain substances.

Browse More Insights

Frequently Asked Questions

Updated on: Jul 26, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.